Navigation
Palmitoylethanolamide in the treatment of chronic pain: A systematic review and meta-analysis of double-blind randomized controlled trials
Although there are few effective therapies for chronic pain, it is a major source of morbidity. Research has shown that Palmitoylethanolamide (PEA), a naturally occurring fatty acid amide, may be a promising intervention in the management of inflammatory and neuropathic pain. While emerging evidence suggests its potential in managing chronic pain, its use remains debated. The purpose of this study by Lang-Illievich et al. (2023) was to evaluate the effectiveness of PEA as an analgesic for chronic pain by doing a systematic review and meta-analysis. A comprehensive literature search was carried out utilizing the MEDLINE and Web of Science databases to find double-blind, randomized controlled studies comparing PEA to active therapies or placebo for chronic pain. Two reviewers individually checked every piece. Pain intensity was the main outcome, and a random effects statistical model was used for a meta-analysis. A narrative analysis examined secondary outcomes, such as side effects, functional status, and quality of life. Of the 253 different articles, 11 trials with 774 patients were analyzed. When compared to comparators, PEA considerably decreased pain ratings, according to the meta-analysis. Furthermore, several trials showed increased functional status and quality of life, and no significant adverse effects were noted in any of the studies that reported PEA. PEA is an efficient and well-tolerated therapy for chronic pain, according to this comprehensive review and meta-analysis. Further research is needed to establish PEA’s optimal dosage and administration parameters in managing chronic pain. [NPID: Palmitoylethanolamide, n-(2hydroxyethyl)-palmitamide, impulsin, palmidrol, chronic pain, analgesia, quality of life]
Year: 2023
